Cost‐effectiveness of fenfluramine as add‐on treatment in the management of Dravet Syndrome: A real‐world multicenter study

Documenti analoghi

• Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysis
  di: Renzo Guerrini, et al.
  Pubblicazione: (2024)
• Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox–Gastaut syndrome in clinical practice
  di: Elaine C. Wirrell, et al.
  Pubblicazione: (2024)
• Successful use of cannabidiol in nonconvulsive status epilepticus in Angelman syndrome
  di: Nicola Pietrafusa, et al.
  Pubblicazione: (2024)
• Seizures influence sleep macrostructure and the sleep–wake circadian rhythm in Dravet syndrome
  di: Alberto Cossu, et al.
  Pubblicazione: (2025)
• Is there really evidence for neurodegeneration in Dravet syndrome? Commentary on the publication by Selvarajah et al.
  di: Sanjay M. Sisodiya, et al.
  Pubblicazione: (2025)